Concord Medical's Chang'an Hospital and Fox Chase Cancer Center Sign Strategic Alliance Agreement
BEIJING, July 18, 2012 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that its subsidiary Chang'an Hospital has signed a strategic alliance agreement with Fox Chase Cancer Center (FCCC).
Under the agreement, Fox Chase Cancer Center will provide support of management, treatment, technology and research to Chang'an Hospital, including protocols and clinical practice guidelines on cancer surgery, chemotherapy, radiotherapy, gene therapy and prevention.
In particular, FCCC will send clinical and management experts to Chang'an Hospital to practice, give lectures and inspect annual quality control standards. At the same time, FCCC will accept management and technical personnel from Chang'an Hospital to study and train there. In addition, FCCC will provide remote diagnosis and treatment programs to Chang'an Hospital. The two organizations will jointly conduct cancer clinical and fundamental research, and share information and research results.
Dr. Jianyu Yang, Chairman and CEO of Concord Medical, said, "We are very pleased to have Chang'an Hospital partner with Fox Chase Cancer Center, one of the well-respected cancer institutions in the world. Our strategic partnership will leverage the technological and management strengths of FCCC to help Chang'an Hospital become a leading hospital focused in cancer treatment and diagnosis in northwestern China."
Fox Chase Cancer Center, now part of Temple Health, was an independent, nonprofit institution formed in 1974 by the union of American Oncologic Hospital (one the the nation's first cancer hospitals, established in 1904) and the Institute for Cancer Research (founded